Recarbrio
Payments companies reported to CMS as associated with Recarbrio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Recarbrio, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Recarbrio
These are the largest totals companies reported as associated with Recarbrio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Andrew Shorr | Washington, DC | Pulmonary Disease | $16,703.38 |
| Genovefa Papanicolaou | New York, NY | Infectious Disease | $12,158.65 |
| William Harley | Charlotte, NC | Infectious Disease | $11,484.08 |
| Joshua Rosenberg | Brooklyn, NY | Critical Care Medicine (Internal Medicine) | $11,084.11 |
| Alexander Evens | Turlock, CA | Infectious Disease | $8,919.82 |
| Michael Niederman | New York, NY | Pulmonary Disease | $8,325.13 |
| Rajkumar Dasgupta | Pasadena, CA | Pulmonary Disease | $5,505.00 |
| Roy Chemaly | Houston, TX | Infectious Disease | $4,965.50 |
| Kerry Cleveland | Memphis, TN | Infectious Disease | $4,767.97 |
| Javeed Siddiqui | Roseville, CA | Infectious Disease | $4,391.45 |
Prescribed Recarbrio?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.